TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA™ Phase 1 study for TSC-101 in patients with hematologic (heme) malignancies. The data, generated using a commercial-ready manufacturing process, showed promising efficacy and a consistent safety profile, supporting the company's plan to initiate a pivotal Phase 3 study.
Key Details
- Primary Efficacy: 11 of 14 dosed patients (79%) achieved complete donor chimerism within approximately three weeks of their first TSC-101 infusion, a key early indicator of efficacy.
- Cohort C Details: 19 patients were enrolled, with a ~90% (17/19) manufacturing success rate using the commercial-ready process; 14 patients proceeded to transplant and received at least one infusion of TSC-101.
- Safety & Next Steps: TSC-101 was reported to be generally well-tolerated. The company remains on track to enroll the first patient in its pivotal Phase 3 ALLOHA-2 study in June 2026.